Advertisement

Alpine Immune Sciences, Inc. ALPN

Set alert

Price alert · ALPN

All alert types
64.97 +64.97 —

Day range unavailable

52-week range unavailable

Open
—
Prev close
0.00
Mkt cap
4.46B
Vol
0
Avg vol
0
EPS
0.00
P/E
0.00
Div yield
0.00%
More statistics
Low
—
High
—
Forward P/E
-32.48
Beta
0.97
Short ratio
0.96
Inst. own
99.47%
Dividend
0.00
Ex-div date
Earnings
May 9, 2024
50-d avg
53.15
200-d avg
26.84
1y target
62.00

2Y chart

Chart tools
Interval

Events in this range
  • Mar 23, 2023Earnings: —; estimate -0.27; surprise —%
  • May 11, 2023Earnings: —; estimate -0.37; surprise —%
  • Aug 14, 2023Earnings: —; estimate -0.38; surprise —%
  • Aug 30, 2023Rating: HC Wainwright & Co. · Buy → Buy
  • Aug 31, 2023Rating: Wedbush · Outperform → Outperform
  • Sep 12, 2023Rating: HC Wainwright & Co. · Buy → Buy
  • Oct 4, 2023Rating: RBC Capital · — → Outperform
  • Oct 17, 2023Rating: Berenberg · — → Buy
  • Nov 14, 2023Earnings: —; estimate -0.35; surprise —%
  • Mar 18, 2024Earnings: —; estimate -0.32; surprise —%
  • May 9, 2024Earnings: —; estimate -0.43; surprise —%
Signals (110)
NameDateAgo
MACD: Sell SignalApr 30, 20242 years ago
MACD: Buy SignalApr 10, 20242 years ago
RSI: OverboughtApr 10, 20242 years ago
MACD: Sell SignalMar 25, 20242 years ago
MACD: Buy SignalMar 21, 20242 years ago
RSI: OverboughtMar 19, 20242 years ago
MACD: Sell SignalMar 8, 20242 years ago
RSI: OverboughtFeb 22, 20242 years ago
RSI: OverboughtFeb 15, 20242 years ago
RSI: OverboughtFeb 7, 20242 years ago
MACD: Buy SignalJan 26, 20242 years ago
RSI: OverboughtJan 26, 20242 years ago
MACD: Sell SignalDec 28, 20232 years ago
RSI: OverboughtDec 8, 20232 years ago
RSI: OverboughtDec 4, 20232 years ago
SMA: BullishNov 2, 20233 years ago
RSI: OverboughtNov 2, 20233 years ago
SMA: BullishOct 31, 20233 years ago
MACD: Buy SignalOct 31, 20233 years ago
SMA: BearishOct 23, 20233 years ago
RSI: OversoldOct 23, 20233 years ago
MACD: Sell SignalOct 10, 20233 years ago
MACD: Buy SignalOct 5, 20233 years ago
SMA: BearishSep 19, 20233 years ago
SMA: BullishSep 15, 20233 years ago
SMA: BearishSep 12, 20233 years ago
SMA: BullishSep 8, 20233 years ago
SMA: BearishSep 7, 20233 years ago
MACD: Sell SignalAug 14, 20233 years ago
RSI: OverboughtAug 8, 20233 years ago
RSI: OverboughtAug 1, 20233 years ago
RSI: OverboughtJul 21, 20233 years ago
MACD: Buy SignalJul 17, 20233 years ago
MACD: Sell SignalJun 23, 20233 years ago
MACD: Buy SignalJun 20, 20233 years ago
RSI: OverboughtJun 20, 20233 years ago
MACD: Sell SignalJun 15, 20233 years ago
MACD: Buy SignalJun 12, 20233 years ago
RSI: OverboughtJun 12, 20233 years ago
MACD: Sell SignalJun 9, 20233 years ago
RSI: OverboughtJun 1, 20233 years ago
RSI: OverboughtMay 19, 20233 years ago
SMA: BullishMay 10, 20233 years ago
SMA: BullishMay 10, 20233 years ago
SMA: BearishMay 9, 20233 years ago
SMA: BullishMay 8, 20233 years ago
MACD: Buy SignalMay 5, 20233 years ago
MACD: Sell SignalMay 3, 20233 years ago
SMA: BearishMay 2, 20233 years ago
SMA: BullishApr 28, 20233 years ago
MACD: Buy SignalApr 28, 20233 years ago
SMA: BearishApr 14, 20233 years ago
SMA: BullishApr 13, 20233 years ago
SMA: BearishApr 11, 20233 years ago
SMA: BearishApr 4, 20233 years ago
SMA: BearishApr 4, 20233 years ago
MACD: Sell SignalApr 4, 20233 years ago
SMA: BullishApr 3, 20233 years ago
MACD: Buy SignalApr 3, 20233 years ago
SMA: BullishMar 31, 20233 years ago
SMA: BearishMar 30, 20233 years ago
SMA: BearishMar 30, 20233 years ago
SMA: BullishMar 29, 20233 years ago
SMA: BullishMar 29, 20233 years ago
SMA: BearishMar 24, 20233 years ago
SMA: BearishMar 24, 20233 years ago
MACD: Sell SignalMar 24, 20233 years ago
SMA: BullishMar 23, 20233 years ago
SMA: BearishMar 21, 20233 years ago
MACD: Buy SignalMar 16, 20233 years ago
SMA: BullishMar 15, 20233 years ago
SMA: BullishMar 14, 20233 years ago
SMA: BearishMar 10, 20233 years ago
SMA: BearishMar 9, 20233 years ago
SMA: BullishFeb 27, 20233 years ago
SMA: BearishFeb 24, 20233 years ago
MACD: Sell SignalFeb 23, 20233 years ago
MACD: Buy SignalFeb 17, 20233 years ago
MACD: Sell SignalJan 24, 20233 years ago
RSI: OverboughtJan 12, 20233 years ago
MACD: Buy SignalDec 30, 20223 years ago
SMA: BullishDec 29, 20223 years ago
MACD: Sell SignalDec 28, 20223 years ago
SMA: BearishDec 27, 20223 years ago
SMA: BullishDec 14, 20223 years ago
MACD: Buy SignalDec 14, 20223 years ago
MACD: Sell SignalDec 9, 20223 years ago
SMA: BearishDec 6, 20223 years ago
SMA: BullishDec 2, 20223 years ago
SMA: BearishNov 28, 20223 years ago
SMA: BullishNov 25, 20223 years ago
MACD: Buy SignalNov 1, 20224 years ago
RSI: OversoldOct 27, 20224 years ago
MACD: Sell SignalOct 20, 20224 years ago
RSI: OversoldOct 20, 20224 years ago
MACD: Buy SignalOct 14, 20224 years ago
MACD: Sell SignalOct 10, 20224 years ago
MACD: Buy SignalOct 4, 20224 years ago
MACD: Sell SignalSep 19, 20224 years ago
MACD: Buy SignalSep 8, 20224 years ago
MACD: Sell SignalAug 19, 20224 years ago
SMA: BearishAug 17, 20224 years ago
SMA: BullishAug 16, 20224 years ago
SMA: BearishAug 15, 20224 years ago
SMA: BullishAug 12, 20224 years ago
SMA: BearishAug 11, 20224 years ago
SMA: BullishAug 10, 20224 years ago
SMA: BearishAug 8, 20224 years ago
MACD: Buy SignalAug 4, 20224 years ago
MACD: Sell SignalJul 25, 20224 years ago

Key statistics

Market cap
4.46B
Enterprise value
4.16B
Trailing P/E
0.00
Forward P/E
-32.48
PEG ratio
0.00
Price / sales
78.85
Price / book
12.80
EPS (TTM)
-0.64
Beta
0.97
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
-65.17%
Revenue (TTM)
56.52M
Revenue growth
-25.10%
Free cash flow
-41.41M
Total cash
305.66M
Total debt
9.65M
Return on equity
-14.67%
Shares outstanding
68.60M
Short % of float
8.27%
50-day average
53.15
200-day average
26.84

Analyst view

Consensus: buy

Buy
Price target (mean) 62.00 -4.6% downside
Target (low)
44.00
Target (mean)
62.00
Target (high)
65.00
Ratings (0m) 3 2 buy · 1 hold · 0 sell
  • Strong buy2
  • Buy0
  • Hold1
  • Sell0
  • Strong sell0

Next earnings

May 9, 2024

Expected May 9, 2024. Consensus EPS estimate -0.42.

Earnings history

Financials — quick view

All financials
ALPN Revenue — quarterly 7.03M
2020-Q2 20202020-Q3 20202020-Q4 20202021-Q1 20212021-Q2 20212021-Q3 20212021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 2024
ALPN Net income — quarterly -17.92M
2020-Q2 20202020-Q3 20202020-Q4 20202021-Q1 20212021-Q2 20212021-Q3 20212021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 2024
ALPN EPS — quarterly -0.28
2020-Q2 20202020-Q3 20202020-Q4 20202021-Q1 20212021-Q2 20212021-Q3 20212021-Q4 20212022-Q1 20222022-Q2 20222022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 2024

Earnings

ALPN recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
May 9, 2024Mar 1, 2024-0.43———
Mar 18, 2024Dec 1, 2023-0.32———
Nov 14, 2023Sep 1, 2023-0.35———
Aug 14, 2023Jun 1, 2023-0.38———
May 11, 2023Mar 1, 2023-0.37———
Mar 23, 2023Dec 1, 2022-0.27———

Upgrades / downgrades

ALPN analyst upgrades and downgrades
DateFirmActionFromTo
Oct 17, 2023Berenberginit—Buy
Oct 4, 2023RBC Capitalinit—Outperform
Sep 12, 2023HC Wainwright & Co.reitBuyBuy
Sep 10, 2023OppenheimermainOutperformOutperform
Aug 31, 2023WedbushreitOutperformOutperform
Aug 30, 2023HC Wainwright & Co.reitBuyBuy

About Alpine Immune Sciences, Inc.

Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington. As of May 20, 2024, Alpine Immune Sciences, Inc. operates as a subsidiary of Vertex Pharmaceuticals Incorporated.

Sector
Healthcare
Industry
Biotechnology
Country
United States

News

Your note

Sign in to keep a note on ALPN — it syncs with the Stock Master app.

Insider holders

ALPN insider holders
InsiderRelationLatest transactionDateShares held
CUI XIANGMINDirector and Beneficial Owner of more than 10% of a Class of SecurityConversion of Exercise of derivative securityJan 17, 20240
DECHENG CAPITAL CHINA LIFE SCIENCES USD FUND III, L.P.Beneficial Owner of more than 10% of a Class of SecurityConversion of Exercise of derivative securityJan 17, 20246,582,380
DURAND REMYOfficerConversion of Exercise of derivative securityMay 7, 2024133,392
FUHS ULRICH MARTINOfficerConversion of Exercise of derivative securityMay 7, 202430,120
GOLD MITCHELL HChief Executive OfficerConversion of Exercise of derivative securityMay 7, 20242,736,400
ORBIMED ADVISORS, L.L.C.UnknownConversion of Exercise of derivative securityJan 10, 20240

Institution ownership

ALPN institution ownership
Holder% heldSharesValueReported
Decheng Capital Management III (Cayman), LLC13.63%6,708,28868.96MJun 29, 2023
RA Capital Management, L.P.9.53%4,691,17848.23MJun 29, 2023
Orbimed Advisors LLC.8.30%4,081,59241.96MJun 29, 2023
Great Point Partners LLC6.84%3,363,68834.58MJun 29, 2023
Frazier Life Sciences Management, L.P.6.07%2,985,75730.69MJun 29, 2023
Lynx1 Capital Management Lp5.43%2,670,47227.45MJun 29, 2023

Fund ownership

ALPN fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund1.73%851,8298.76MJun 29, 2023
iShares Russell 2000 ETF1.49%730,6619.02MAug 30, 2023
Fidelity Advisor Biotechnology Fund0.80%394,0004.94MJul 30, 2023
Vanguard Extended Market Index Fund0.70%345,1083.55MJun 29, 2023
Fidelity Small Cap Index Fund0.58%287,0373.60MJul 30, 2023
iShares NASDAQ Biotechnology ETF0.42%206,0492.54MAug 30, 2023
Advertisement